Clik here to view.
Clik here to view.
幹細胞移植歴のない多発性骨髄腫患者を対象としたファーストライン維持療法としてのニンラーロ（イキサゾミブ）の第3相試験で主要評価項目を達成
米マサチューセッツ州ケンブリッジ & 大阪 ビジネスワイヤ） — 武田薬品工業株式会社（TSE: 4502/NYSE:...
View ArticleClik here to view.
NINLAROTM (ixazomib)作为未接受干细胞移植的多发性骨髓瘤患者一线维持治疗的3期试验达到主要终点
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE: 4502/NYSE: TAK)（“武田”）今天宣布，随机、3期TOURMALINE-MM4研究达到主要终点无进展生存(PFS)。该试验比较单药口服NINLARO™...
View ArticleClik here to view.
Clik here to view.
NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen...
TOKYO & BASEL, Switzerland & MANNHEIM, Germany NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, and VAXIMM AG, a Swiss/German biotech company focused on...
View ArticleClik here to view.
Notice of Business Alliance between Promethera® Biosciences SA and MEDIPAL...
MONT-SAINT-GUIBERT, Belgium Promethera® Biosciences SA (“Promethera®”) and MEDIPAL HOLDINGS CORPORATION (“MEDIPAL”) today announced that they have entered into a business alliance agreement. In...
View ArticleClik here to view.
注意-更正并替换：Promega与Merck达成全球合作共同研发针对Keytruda®的微卫星不稳定性(MSI)检测伴随诊断试剂
美国威斯康星州麦迪逊市 (美国商业资讯) Promega(普洛麦格)与Merck(美国和加拿大以外称为MSD默沙东)达成一项全球合作，共同开发Promega的微卫星不稳定性(MSI)检测产品作为说明书中标注的与 Merck的抗PD-1治疗药物Keytruda®...
View ArticleClik here to view.
クックメディカル、アジア太平洋地域におけるリーダーシップを変更成長と医師との関係構築強化にフォーカス
香港 （ビジネスワイヤ）– クックメディカルは、ジャン・マルク・クレセルがアジア太平洋地域の副社長兼ディレクターに就任したことを発表しました。 本プレスリリースではマルチメディアを使用しています。リリースの全文はこちらをご覧ください。：https://www.businesswire.com/news/home/20191112006129/ja/ Jean-Marc Creissel...
View ArticleClik here to view.
库克医疗：调整亚太区领导层布局，强化与医生合作并着眼区域业务发展
香港 库克医疗欣然宣布Jean-Marc Creissel为新任亚太区副总裁及总监。 就任新职位后，Creissel先生将带领亚太区团队将库克医疗转型成一家真正现代化的全球性公司，并始终把病患、客户和员工置为企业日常运营的最核心考量。同时，他也将提升亚太区团队在世界各地交付创新型医疗解决方案的能力，提高病人满意度。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
Cook Medical’s Leadership Updates in Asia-pacific Reinforce Focus on Growth...
HONG KONG Cook Medical announced today that Jean-Marc Creissel has been named vice president and director of Asia-Pacific. This press release features multimedia. View the full release here:...
View ArticleClik here to view.
NEC和VAXIMM宣布合作推进个体化新抗原癌症疫苗
东京和瑞士巴塞尔和德国曼海姆 (美国商业资讯)–IT和网络技术领导者NEC Corporation (NEC; TOKYO: 6701)和专注于开发口服T细胞免疫治疗药物的瑞士/德国生物技术公司VAXIMM AG今天宣布，两家公司已签署临床试验战略合作协议和股权投资协议，以开发新型个体化新抗原癌症疫苗。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
武田将在美国血液学会(ASH)第61届年会上重点介绍扩大后的肿瘤和血液产品阵容
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE: 4502/NYSE:TAK)今天宣布将在2019年12月7-10日佛罗里达州奥兰多召开的美国血液学会第61届年会上呈报总计29篇公司赞助的摘要，凸显公司对促进血癌和出血障碍治疗的承诺。 追求肿瘤学和出血障碍领域的突破、患者为中心的创新...
View ArticleClik here to view.
Deciphera Pharmaceuticals, Inc. to Present Data from DCC-3014 and Ripretinib...
WALTHAM, Mass. Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced preliminary data from the ongoing Phase 1 study of DCC-3014, an oral inhibitor of CSF1R, including initial data in...
View ArticleClik here to view.
武田薬品が第61回米国血液学会（ASH）年次総会でオンコロジーおよび血液疾患の領域における拡大した製品ポートフォリオに光を当てる
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:...
View ArticleClik here to view.
Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Independent...
PACIFIC PALISADES, Calif. Aadi Bioscience, Inc. (Aadi), a privately held clinical stage biopharmaceutical company, today released its independent radiology reviewed data from the nab-sirolimus...
View ArticleClik here to view.
Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) will host an R&D meeting today beginning at 12:30 p.m. EST in New York City to outline how its science-first,...
View ArticleClik here to view.
VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179...
CAMBRIDGE, Mass. & BEIJING & DURHAM, N.C. VBI Vaccines (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology...
View ArticleClik here to view.
Oncternal Therapeutics Announces Presentation of Interim Clinical Data on...
SAN DIEGO Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of interim...
View ArticleClik here to view.
FETROJA® (cefiderocol) Approved by the FDA for Treatment of Complicated...
OSAKA, Japan & FLORHAM PARK, N.J. Shionogi & Co., Ltd. (hereafter “Shionogi”) today announced the U.S. Food and Drug Administration (FDA) has approved FETROJA® (cefiderocol) for patients 18...
View ArticleSinovac Reports Unaudited Third Quarter 2019 Financial Results
BEIJING Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the third...
View Article